RecruitingNot ApplicableNCT07395635
Phase II Trial of Immunonutrition in Hepatectomy
Impact of Immunonutrition in Patients Undergoing Hepatectomies for Liver Tumors: A Randomized Controlled Phase II Trial
Sponsor
Tata Memorial Centre
Enrollment
100 participants
Start Date
Oct 3, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A randomised open labelled study to evalaute the impact of immunonutrition in Patients Undergoing Hepatectomies for Liver Tumors
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria3
- Patients with liver tumors planned for major hepatectomies (defined as resection of \>/= 3 liver segments)
- Age above 18 years
- ASA class I-III
Exclusion Criteria3
- Preoperative severe renal failure (estimated glomerular filtration rate \< 30 ml/min)
- History of hypersensitivity to arginine, omega-3 fatty acids, or nucleotide 3. Inability to take oral nutrition
- \. Pregnancy 5. Mental condition rendering the subject unable to understand the nature, endpoints and consequences of the trial
Interventions
DIETARY_SUPPLEMENTImmunonutrition
In addition to their usual intake, patients in the intervention arm will be prescribed for each of the 7 consecutive days preceding surgery 6-9 scoops PENTASURE Immunomax® powder (120-180g per day)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07395635
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations